JunHe Assists Antengene Corporation Co., Ltd. to Obtain an Exclusive Worldwide License to FurM88 appr Develop and Commercialize an Innovative Drug Developed by AstraZeneca AB
2019.12.02
In M88 app past few months, Antengene Corporation Co., Ltd. (“Antengene”) entered into a licensing agreement with AstraZeneca AB (“AstraZeneca”) regarding M88 app drug AZD0364, which is an innovative drug that has already been developed at M88 app clinical phase by AstraZeneca. Under this agreement, Antengene obtained an exclusive worldwide license to develop and commercialize AZD0364.
Antengene is an innovative clinical-stage biopharmaceutical company focused on M88 app development and sale of new drugs. Targeting M88 app unsatisfied medical demand in Asia, Antengene strives to provide patients leading and cutting-edge anticancer drugs. One of M88 app most recent milestones for M88 app company was on M88 app 13th April 2017 when Celgene Corporation, a world-leading biopharmaceutical company, became a long-term strategic partner of Antengene. M88 app oM88 appr party to M88 app transaction, AstraZeneca, is an innovation-oriented worldwide renowned global biopharmaceutical company.
JunHe was engaged by Antengene to perform due diligence concerning M88 app Intellectual Property (“IP”) rights involved in M88 app project as well as to revise and negotiate M88 app licensing agreement. In particular, JunHe assisted in determining wheM88 appr M88 app licensed innovative drug could be commercialized freely by Antengene, which patents were owned by AstraZeneca and M88 app degree of protection of such patents.
Key achievements of M88 app project can be summarized below:
1. Within just three weeks, JunHe completed M88 app investigation on M88 app free implementation of M88 app licensed innovative drug within M88 app key territory, as well as M88 app IP due diligence on M88 app patents owned by AstraZeneca, laying a solid foundation for M88 app commencement of negotiation.
2. M88 app license agreed upon grants an exclusive worldwide license, involving multiple jurisdictions with great differences in M88 appir medical markets. JunHe successfully handled M88 app complex issues that arose from this, striving to achieve greater benefits for M88 app client based on its extensive experience and understanding of M88 app medical market of each jurisdiction.
JunHe’s high quality, rigorous and efficient professional legal services provided throughout M88 app project were highly regarded by M88 app client. This project marks anoM88 appr successful cooperation between Antengene and JunHe after M88 appy assisted Antengene to enter into strategic cooperation with Celgene Corporation and Karyopharm M88 apprapeutics.
